Market closed
Bausch + Lomb/$BLCO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bausch + Lomb
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Ticker
$BLCO
Sector
Trading on
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Vaughan, Canada
Employees
13,500
Website
Bausch + Lomb Metrics
BasicAdvanced
$4B
-
-$1.03
0.54
-
Price and volume
Market cap
$4B
Beta
0.54
52-week high
$21.69
52-week low
$10.45
Average daily volume
1.1M
Financial strength
Current ratio
1.561
Quick ratio
0.71
Long term debt to equity
74.444
Total debt to equity
75.066
Interest coverage (TTM)
0.33%
Management effectiveness
Return on assets (TTM)
0.53%
Return on equity (TTM)
-5.36%
Valuation
Price to revenue (TTM)
0.832
Price to book
0.63
Price to tangible book (TTM)
-2.47
Price to free cash flow (TTM)
-23.901
Growth
Revenue change (TTM)
11.94%
Earnings per share change (TTM)
6.69%
3-year revenue growth (CAGR)
8.57%
3-year earnings per share growth (CAGR)
27.15%
Bausch + Lomb News
AllArticlesVideos
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Business Wire·8 hours ago
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
Business Wire·1 day ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO
Accesswire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Bausch + Lomb stock?
Bausch + Lomb (BLCO) has a market cap of $4B as of May 09, 2025.
What is the P/E ratio for Bausch + Lomb stock?
The price to earnings (P/E) ratio for Bausch + Lomb (BLCO) stock is 0 as of May 09, 2025.
Does Bausch + Lomb stock pay dividends?
No, Bausch + Lomb (BLCO) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Bausch + Lomb dividend payment date?
Bausch + Lomb (BLCO) stock does not pay dividends to its shareholders.
What is the beta indicator for Bausch + Lomb?
Bausch + Lomb (BLCO) has a beta rating of 0.54. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.